Dublin, June 24, 2024 (GLOBE NEWSWIRE) — The “Global Enzyme-Linked Immunosorbent Assay (ELISA) Market – Forecast 2024 to 2029” report has been added to the ResearchAndMarkets.com’s The offer of
The global enzyme-linked immunosorbent assay (ELISA) market is projected to grow at a CAGR of 5.56% rising from USD 2.138 billion in 2022 to USD 3.123 billion in 2029.
Common diagnostic applications of ELISA are HIV infection, pregnancy tests, protein detection, etc. The ELISA market is expected to show robust growth during the forecast period. The increase can be attributed to the increased incidence of infectious and chronic diseases, which require ELISA as a cost-effective diagnostic tool. However, stringent regulatory requirements as well as unfavorable reimbursement policies related to ELISA may hamper the market growth over the given time frame.
The increasing prevalence of infectious diseases is anticipated to drive the growth of the market.
One of the major drivers driving the expansion of the market is the increasing prevalence of infectious diseases such as HIV, hepatitis, malaria, dengue, and influenza, among other diseases. At the end of 2021, WHO estimated that there were 38.4 million HIV-positive individuals worldwide, with more than two-thirds of them living in Africa. The WHO also claimed that dengue fever was among the top ten health threats facing the world. Over the past 50 years, the incidence of dengue has increased by about 3000% worldwide. WHO also estimated that more than 296 million individuals worldwide have hepatitis B infection as of 2019.
The demand for diagnostics is expected to increase as a result of the increased occurrence of infectious diseases. The market is projected to expand due to the increasing use of the latest diagnostic techniques for screening these disorders, such as enzyme-linked immunosorbent assays.
Moreover, the increase in the geriatric population, which globally is at risk of contracting diseases and chronic diseases and requires routine diagnosis, is expected to drive the market expansion. Compared to younger individuals, potentially dangerous diseases are more likely in older patients, according to the NCBI (National Center for Biotechnology Information), which published this information in 2021. Thus, these factors are predicted to increase significantly market growth by increasing demand for enzyme-linked immunosorbent assays.
The disease diagnostics segment is anticipated to drive the growth of the market.
Due to the increasing use of enzyme-linked immunosorbent assay tests for the diagnosis of specific antigens, a significant share of the disease diagnostics market is anticipated. In 2022, WHO estimated that noncommunicable diseases caused about 41 million deaths each year, equivalent to 71% of all deaths worldwide. Due to these phenomena, there is now a greater need for efficient diagnostic techniques such as ELISA for rapid detection to minimize the incidence of death.
Furthermore, according to the Global Cancer Observatory, there were an estimated 19.3 million new cancer cases and nearly 10.0 million cancer deaths worldwide in 2020. Since ELISA is a useful instrument for antigen evaluation, the increasing incidence of cancer worldwide is increasing the demand remove it.
Enzyme-linked immunosorbent assay can be used to detect both breast cancer antigens and prostate cancer antigens, according to a 2020 Nature Scientific study. Such accurate antigen screening and cost-effective diagnosis are envisioned increase the demand for ELISA and drive the expansion of the market during the analyzed period.
North America is expected to hold a significant share in the market
Due to the rapid development of technological advancements in screening instruments such as ELISA, the US is likely to dominate the global market. The increasing incidence of multiple infectious and chronic diseases in this demographic is contributing to the high demand for enzyme-linked immunosorbent assay. For example, the CDC (Center for Disease Control and Prevention) reported in 2022 that over 60% of Americans had at least one chronic disease, such as cancer, cardiovascular disease, or stroke.
The market in this region is expected to grow as a result of increased R&D spending as well as numerous diagnostic funding initiatives. Firms listed in the biotech index expanded their R&D spending by about 16% on average in 2020 to US$284.25 million, based on the 2020 Binder Dijker Otte USA Reports.
Main attributes:
| The report attribute | The details |
| No. of Pages | 135 |
| Forecast period | 2022 – 2029 |
| Estimated market value (USD) in 2022 | 2.14 billion dollars |
| Estimated market value (USD) by 2029 | 3.12 billion dollars |
| Compound Annual Growth Rate | 5.5% |
| Regions covered | global |
Competitive environment and analysis
- Key players and strategy analysis
- Market Share Analysis
- Mergers, acquisitions, agreements and collaborations
- Competitive panel
Company Profiles
- Pestka Biomedical Laboratories, Inc.
- Diaklon SAS
- Thermo Fisher Scientific Inc.
- Azure Biosystems Inc.
- R&D Systems, Inc
- RayBiotech, Inc.
- Elabscience
- BioLegend, Inc.
- Randox Toxicology
- STEMCELL Technologies Inc.
- Genway Biotech, Inc.
Segmentation:
By type
- Indirect ELISA
- Sandwich ELISA
- Competitive ELISA
By Application
- Food and drink
- Vaccine development
- Immunology
- diagnostic
- Drug monitoring
- Others
By End Users
- Pharmaceutical industries
- Hospitals and clinics
- Diagnostic centers
- Others
According to Geography
- North America
- United States
- Canada
- Mexico
- South America
- Brazil
- Argentinian
- Others
- Europe
- uk
- Germany
- France
- Ital
- Spain
- Others
- Middle East and Africa (MEA)
- Saudi Arabia
- UAE
- Israel
- Others
- Asia Pacific
- Japan
- China
- Indian
- Australia
- South Korea
- Indonesia
- Thailand
- Taiwan
- Others
For more information about this report visit https://www.researchandmarkets.com/r/l0b33j
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, leading companies, new products and the latest trends.
-
Global Enzyme-Linked Immunosorbent Assay (ELISA) Market.
#Global #EnzymeLinked #Immunosorbent #Assay #ELISA #Market #Research #ELISA #Key #CostEffective #Diagnostic #Tool #Multiple #Diagnostic #Applications #Drives #Adoption #Growth
Image Source : www.globenewswire.com